Sharon Mates

1.8k citations

41 papers · 862 indexed · h-index 16

Impact in

Biological Psychiatry top 1%
- Tryptophan and brain disorders
Psychiatry and Mental health top 2%
- Schizophrenia research and treatment
- Bipolar Disorder and Treatment

Papers in

Biological Psychiatry 19
- Tryptophan and brain disorders 19
Psychiatry and Mental health 17
- Bipolar Disorder and Treatment 11
- Schizophrenia research and treatment 10

Co-authors: Jennifer S. Lund Robert E. Davis Kimberly E. Vanover Christoph U. Correll John M. Kane Andrew Satlin Gretchen L. Snyder Carol A. Tamminga
Journals: Schizophrenia Bulletin (7 papers)Schizophrenia Research (6 papers)CNS Spectrums (6 papers)International Clinical Psychopharmacology (4 papers)Psychopharmacology (3 papers)
Partner nations: United States Germany Sweden

In The Last Decade

Sharon Mates

40 papers receiving 812 citations

Peers

Countries citing papers authored by Sharon Mates

Since Specialization

Citations

This map shows the geographic impact of Sharon Mates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Mates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Mates more than expected).

Fields of papers citing papers by Sharon Mates

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon Mates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Mates. The network helps show where Sharon Mates may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sharon Mates, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sharon Mates Line = papers co-authored together Sharon Mates links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study International Clinical Psychopharmacology ·Mauricio Tohen, Suresh Durgam, Jeffrey A. Sparks, Changzheng Chen, Robert E. Davis, Sharon Mates	2025	1
2	Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial International Clinical Psychopharmacology ·Christoph U. Correll, Suresh Durgam, J.H. LECK, Hassan Lakkis, Changzheng Chen, Kimberly E. Vanover, Sharon Mates, Robert E. Davis	2025	1
3	Adjunctive lumateperone (ITI‐007) in the treatment of bipolar depression: Results from a randomized placebo‐controlled clinical trial Bipolar Disorders ·Trisha Suppes, Suresh Durgam, J.H. LECK, Richard Chen, Hassan Lakkis, Robert E. Davis, Andrew Satlin, Kimberly E. Vanover, Sharon Mates, Roger S. McIntyre, Mauricio Tohen	2023	16
4	Long-Term Lumateperone Treatment in Bipolar Disorder: Six-Month Open-Label Extension Study CNS Spectrums ·Mauricio Tohen, Suresh Durgam, J.H. LECK, Н. А. Утемгалиева, Richard Chen, Sharon Mates	2023	2
5	Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial American Journal of Psychiatry ·Joseph R. Calabrese, Suresh Durgam, Andrew Satlin, Kimberly E. Vanover, Robert E. Davis, Richard Chen, J.H. LECK, Sharon Mates, Roy H. Perlis	2021	65
6	Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia Schizophrenia Research ·Christoph U. Correll, Kimberly E. Vanover, Robert E. Davis, Richard Chen, Andrew Satlin, Sharon Mates	2021	23
7	Cardiometabolic Safety of Lumateperone (ITI−007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study in Schizophrenia CNS Spectrums ·J.B. Edwards, Andrew Satlin, Suresh Durgam, Robert E. Davis, Richard Chen, Sharon Mates, Christoph U. Correll	2021	1
8	P.0424 Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: results from a randomised clinical trial European Neuropsychopharmacology ·Lakshmi N. Yatham, Suresh Durgam, J.H. LECK, Chang‐Yo Pan, Robert E. Davis, Sharon Mates, Mauricio Tohen	2021	1
9	A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia Advances in pharmacology ·Gretchen L. Snyder, Kimberly E. Vanover, Robert E. Davis, Peng Li, Allen A. Fienberg, Sharon Mates	2020	21
10	P.468 Cardiometabolic safety of lumateperone (ITI-007): post hoc analyses of short-term randomized trials and an open-label long-term study European Neuropsychopharmacology ·Andrew Satlin, Suresh Durgam, K.E. Vanover, Robert E. Davis, Chang‐Yo Pan, Sharon Mates, C.U. Correll	2020	1
11	Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia Neuropsychopharmacology ·Kimberly E. Vanover, Robert E. Davis, Yun Zhou, Weiguo Ye, James Robert Brašić, Lorena Gapasin, Jelena Saillard, Michal Weingart, Robert E. Litman, Sharon Mates, Dean F. Wong	2018	58
12	Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats Psychopharmacology ·Gretchen L. Snyder, Jos Prickaerts, Ekaterina Sudarkina, Lei Zhang, Hailin Zheng, Wei Yao, Sven Akkerman, Hongwen Zhu, Joseph P. Hendrick, Kimberly E. Vanover, Robert E. Davis, Peng Li, Sharon Mates, Lawrence P. Wennogle	2016	49
13	ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial Biological Psychiatry ·Jeffrey A. Lieberman, Robert E. Davis, Christoph U. Correll, Donald Goff, John M. Kane, Carol A. Tamminga, Sharon Mates, Kimberly E. Vanover	2015	85
14	ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers Psychopharmacology ·Robert E. Davis, Kimberly E. Vanover, Yun Zhou, James Robert Brašić, Maria Guevara, A. N. Bennett, Weiguo Ye, Vanessa Raymont, William D. Willis, Anil Kumar, Lorena Gapasin, D. Ronald Goldwater, Sharon Mates, Dean F. Wong	2015	31
15	Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission Psychopharmacology ·Gretchen L. Snyder, Kimberly E. Vanover, Hongwen Zhu, Diane B. Miller, James P. O’Callaghan, جواد خزائی پول, Peng Li, Qiang Zhang, Vaishnav Krishnan, Joseph P. Hendrick, Eric J. Nestler, Robert E. Davis, Lawrence P. Wennogle, Sharon Mates	2014	96
16	ITI-007, A NEW APPROACH TO THE TREATMENT OF SCHIZOPHRENIA Schizophrenia Research ·Kimberly E. Vanover, Robert E. Davis, Sharon Mates	2014	1
17	Poster #M245 POSITIVE RESULTS WITH ITI-007 FOR THE TREATMENT OF SCHIZOPHRENIA: A RANDOMIZED DOUBLE-BLIND PLACEBO- AND ACTIVE-CONTROLLED PHASE 2 STUDY Schizophrenia Research ·Kimberly E. Vanover, Robert E. Davis, Larry Ereshefsky, Sharon Mates	2014	2
18	ENHANCEMENT OF COGNITION IN SCHIZOPHRENIA VIA INHIBITION OF PHOSPHODIESTERASE-1B AND POTENTIATION OF DOPAMINE D1 RECEPTOR SIGNALING Schizophrenia Research ·Lawrence P. Wennogle, Gretchen L. Snyder, Peng Li, Kimberly E. Vanover, Robert E. Davis, Allen A. Fienberg, Joseph P. Hendrick, Sharon Mates	2010	1
19	ITI-007: A NOVEL THERAPY FOR THE TREATMENT OF SCHIZOPHRENIA AND RELATED PSYCHOSES Schizophrenia Research ·Kimberly E. Vanover, Gretchen L. Snyder, Joseph P. Hendrick, Allen A. Fienberg, Lawrence P. Wennogle, Sharon Mates, Robert E. Davis	2010	1
20	Neuronal composition and development in lamina 4C of monkey striate cortex The Journal of Comparative Neurology ·Sharon Mates, Jennifer S. Lund	1983	57

About Sharon Mates

Sharon Mates is a scholar working on Biological Psychiatry, Psychiatry and Mental health, Pharmacology, Cellular and Molecular Neuroscience and Cognitive Neuroscience, having authored 41 papers that have together received 862 indexed citations. Recurring topics across this work include Tryptophan and brain disorders (19 papers), Bipolar Disorder and Treatment (11 papers), Schizophrenia research and treatment (10 papers), Treatment of Major Depression (9 papers), Neuroscience and Neuropharmacology Research (4 papers), Neural dynamics and brain function (3 papers), Receptor Mechanisms and Signaling (3 papers) and Neurotransmitter Receptor Influence on Behavior (3 papers). The work is most often cited by research in Biological Psychiatry (270 citations), Psychiatry and Mental health (465 citations), Cellular and Molecular Neuroscience (246 citations), Pharmacology (183 citations) and Cognitive Neuroscience (137 citations). Sharon Mates has collaborated with scholars based in United States, Germany and Sweden. Frequent co-authors include Jennifer S. Lund, Robert E. Davis, Kimberly E. Vanover, Christoph U. Correll, John M. Kane, Andrew Satlin, Gretchen L. Snyder, Carol A. Tamminga, Jelena Saillard and Jeffrey A. Lieberman. Their work appears in journals such as Schizophrenia Bulletin, Schizophrenia Research, CNS Spectrums, International Clinical Psychopharmacology and Psychopharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact